Developer docs
API playgroundTry for free, no card

Search company profiles

Soleus Capital

Full company profile

uuid00003vq

Namestring
Soleus Capital
Legal namestring
Soleus Capital
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Soleus Capital is a Greenwich, Connecticut-based healthcare-focused investment firm founded in 2018 that invests across the healthcare lifecycle in biotech, medtech, diagnostics, and genomics, targeting both developmental-stage and commercial-stage companies. The firm operates a multi-fund platform spanning public funds, three private equity vintages (PE Funds I, II, III), a Credit Opportunities Fund, and special purpose vehicles, with limited-partner access gated through the Matrix and AltaReturn institutional investor portals.

The firm generates revenue through capital gains, dividends, and investment income from long/short equity positions in life sciences and biopharma issuers, supplemented by participation in structured royalty financings such as the amended Heidelberg Pharma / HealthCare Royalty arrangement tied to Telix Pharmaceuticals' TLX250-Px. Go-to-market is enterprise field sales: Soleus sources deals through direct relationships with healthcare management teams and co-investor syndicates, executing private placements, PIPEs, follow-on offerings, and underwritten offerings alongside placement agents and joint book-runners including Goldman Sachs, Evercore ISI, and Citizens Capital Markets.

Recent activity (October 2025 through May 2026) includes leading a $30 million oversubscribed PIPE for Aprea Therapeutics, participating in Parabilis Medicines' $305 million Series F, Adlai Nortye's $150 million placement, Prelude Therapeutics' $90 million offering, Quoin Pharmaceuticals' up-to-$104.5 million private placement, and Heidelberg Pharma's $20 million-plus-$25 million royalty transaction, alongside a disclosed ~$63.40 million Vericel public-equity position. Pricing, fee schedules, AUM, and revenue are not publicly disclosed, and the firm files SEC portfolio disclosures consistent with operation as an SEC-registered investment adviser.

Short descriptiontext

Soleus Capital is a Greenwich, Connecticut-based healthcare-focused investment firm that deploys capital across biotech, medtech, diagnostics, and genomics via a multi-fund platform (public funds, three PE vintages, a credit fund, and SPVs), executing private placements, PIPEs, and structured financings alongside tier-one healthcare syndicates.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGreenwich, United States
HQ citystring
Greenwich
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
healthcare private equity, life sciences investing, biotech investment funds, PIPE financings, royalty financing
Industry1 code
PRIMARYFSAKAGAB
SME Term Loans & Growth Capital
Financial & Insurance/Lending & Consumer Finance/Small Business & Microenterprise Lending
NAICS code4 codes
  • Funds, Trusts, and Other Financial Vehicles525
  • Other Investment Pools and Funds5259
  • Portfolio Management and Investment Advice523940
  • Other Financial Investment Activities5239
SIC code1 code
  • Miscellaneous Business Credit Institution6159
Product category
Healthcare Private Equity / Life Sciences Investment Management
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Investment returns / hedge fund performance
TypeManaged Services
Description

Generates returns through long/short equity positions in life sciences and biopharma companies, with reported monthly performance (e.g., -4.9% in January 2026). Revenue consists of capital gains, dividends, and other investment income from portfolio holdings.

institutionalinvestor.com
2Royalty financing income
TypeLicensing Royalties
Description

Provides structured capital against future royalty streams (e.g., USD 20 million upfront plus a future USD 25 million milestone tied to FDA approval of TLX250-Px via Heidelberg Pharma arrangement), earning through royalty monetization rights.

heidelberg-pharma.com
3Fund management fees
TypeManaged Services
Description

Operates multiple fund vehicles (Public Funds, Private Equity Fund III, Credit Opportunities Fund I, Private Equity Fund I/II/SPVs) accessed via investor portals, generating typical asset management fees and/or performance fees.

soleuscapital.com
Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Soleus Capital is a healthcare-focused investment firm that manages a multi-fund platform spanning the entire healthcare lifecycle, from developmental-stage through commercial-stage companies. It invests across biotech, medtech, diagnostics, and genomics via private equity funds, a public fund, a credit opportunities fund, and special purpose vehicles, executing strategies such as PIPEs, private placements, public-equity long/short positions, and structured royalty financings.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Led an oversubscribed $30 million private placement for Aprea Therapeutics (May 2026)
+6 more records
Product overview1 text field

Soleus Capital is a healthcare investment firm that operates a multi-fund platform spanning the healthcare lifecycle, from development-stage companies through commercial companies. Its offering is organized as a platform-plus-modules architecture comprising two investor-portal-hosted suites: a Matrix-hosted suite covering the Public Funds, Private Equity Fund III, and Credit Opportunities Fund I, and an Altar Return-hosted suite covering Private Equity Fund I, Private Equity Fund II, and SPV vehicles. The firm invests across biotech, medtech, diagnostics, and genomics.

Product and service1 record
1Public Funds
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Healthcare-dedicated crossover fund investing across public and private biotech via PIPEs, private placements, and follow-ons. Co-invested with Soleus in Parabilis ($305M Series F), Prelude ($90M offering), and Adlai Nortye, making it a directly comparable sponsor in the same niche.

TypeDirect peer
Description

Healthcare-focused investment manager running life-sciences hedge and private credit strategies with biotech PIPE and private placement activity. Co-invested with Soleus in Adlai Nortye's $150M placement and reported alongside Soleus in monthly biopharma hedge fund performance rankings.

TypeDirect peer
Description

Healthcare-dedicated long/short and private equity manager investing across biotech and medtech stages. Co-invested with Soleus in the Parabilis Series F and Adlai Nortye placement, operating with a similarly lean team and crossover structure.

TypeDirect peer
Description

Healthcare/biotech-focused investment firm running public and private strategies, including PIPEs and venture-style investments in clinical-stage companies. Reported alongside Soleus in monthly biopharma hedge fund performance rankings, making it a direct peer in mandate and structure.

TypeDirect peer
Description

Healthcare-dedicated venture and public equity manager focused on biopharma across development stages. Co-invested with Soleus in Parabilis' $305M Series F and operates with a comparable pure-play life sciences thesis.

TypeDirect peer
Description

Biotech-focused venture and crossover investor participating in private placements and PIPEs across clinical-stage therapeutics. Co-invested with Soleus in Parabilis' Series F, sharing the dedicated healthcare/life sciences mandate.

7AIGH Capital Management
TypeDirect peer
Description

Healthcare-focused investment manager actively participating in biotech PIPE and private placement financings. Co-invested with Soleus in Quoin Pharmaceuticals' $104.5M placement, operating with a similar crossover mandate.

TypeBroad incumbent
Description

One of the largest dedicated healthcare investment firms globally, operating venture, growth, credit, and public equity strategies across biotech, medtech, and diagnostics. Broad incumbent that shares Soleus's vertical focus but operates at significantly larger AUM scale and broader strategy mix.

9Baker Bros. Advisors
TypeBroad incumbent
Description

Healthcare-focused long/short equity and venture manager with deep biotech specialization and large AUM. A broad incumbent peer that competes for the same PIPE and private placement opportunities as Soleus but at substantially larger scale.

TypeBroad incumbent
Description

Pioneering healthcare/tech venture firm co-leading large crossover rounds including Parabilis' $305M Series F alongside Soleus. A broad incumbent that competes for similar early- and growth-stage life sciences opportunities but with a venture-primary rather than crossover/PIPE model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment95 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Soleus Capital

Healthcare Private Equity / Life Sciences Investment Managementsoleuscapital.com

Soleus Capital is a Greenwich, Connecticut-based healthcare-focused investment firm that deploys capital across biotech, medtech, diagnostics, and genomics via a multi-fund platform (public funds, three PE vintages, a credit fund, and SPVs), executing private placements, PIPEs, and structured financings alongside tier-one healthcare syndicates.

What Soleus Capital does

Soleus Capital is a Greenwich, Connecticut-based healthcare-focused investment firm founded in 2018 that invests across the healthcare lifecycle in biotech, medtech, diagnostics, and genomics, targeting both developmental-stage and commercial-stage companies. The firm operates a multi-fund platform spanning public funds, three private equity vintages (PE Funds I, II, III), a Credit Opportunities Fund, and special purpose vehicles, with limited-partner access gated through the Matrix and AltaReturn institutional investor portals.

The firm generates revenue through capital gains, dividends, and investment income from long/short equity positions in life sciences and biopharma issuers, supplemented by participation in structured royalty financings such as the amended Heidelberg Pharma / HealthCare Royalty arrangement tied to Telix Pharmaceuticals' TLX250-Px. Go-to-market is enterprise field sales: Soleus sources deals through direct relationships with healthcare management teams and co-investor syndicates, executing private placements, PIPEs, follow-on offerings, and underwritten offerings alongside placement agents and joint book-runners including Goldman Sachs, Evercore ISI, and Citizens Capital Markets.

Recent activity (October 2025 through May 2026) includes leading a $30 million oversubscribed PIPE for Aprea Therapeutics, participating in Parabilis Medicines' $305 million Series F, Adlai Nortye's $150 million placement, Prelude Therapeutics' $90 million offering, Quoin Pharmaceuticals' up-to-$104.5 million private placement, and Heidelberg Pharma's $20 million-plus-$25 million royalty transaction, alongside a disclosed ~$63.40 million Vericel public-equity position. Pricing, fee schedules, AUM, and revenue are not publicly disclosed, and the firm files SEC portfolio disclosures consistent with operation as an SEC-registered investment adviser.

Soleus Capital firmographics

Firmographics
Name
Soleus Capital
Legal name
Soleus Capital
Website
https://soleuscapital.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Soleus Capital is a Greenwich, Connecticut-based healthcare-focused investment firm that deploys capital across biotech, medtech, diagnostics, and genomics via a multi-fund platform (public funds, three PE vintages, a credit fund, and SPVs), executing private placements, PIPEs, and structured financings alongside tier-one healthcare syndicates.
Ownership category
akta.pro rank

Soleus Capital industry classification

Industry
Product category
Healthcare Private Equity / Life Sciences Investment Management
NAICS
Funds, Trusts, and Other Financial Vehicles (525), Other Investment Pools and Funds (5259), Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)
SIC
Miscellaneous Business Credit Institution (6159)
akta.pro industry
PRIMARYFSAKAGAB
SME Term Loans & Growth Capital
Financial & Insurance/Lending & Consumer Finance/Small Business & Microenterprise Lending

Keywords

  • Healthcare private equity
  • Life sciences investing
  • Biotech investment funds
  • PIPE financings
  • Royalty financing

Where Soleus Capital is headquartered

Location

Headquarters

HQ city
Greenwich
HQ country
United States
HQ region
North America

Markets served

Soleus Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Investment returns / hedge fund performance: Generates returns through long/short equity positions in life sciences and biopharma companies, with reported monthly performance (e.g., -4.9% in January 2026). Revenue consists of capital gains, dividends, and other investment income from portfolio holdings.
  2. Royalty financing income: Provides structured capital against future royalty streams (e.g., USD 20 million upfront plus a future USD 25 million milestone tied to FDA approval of TLX250-Px via Heidelberg Pharma arrangement), earning through royalty monetization rights.
  3. Fund management fees: Operates multiple fund vehicles (Public Funds, Private Equity Fund III, Credit Opportunities Fund I, Private Equity Fund I/II/SPVs) accessed via investor portals, generating typical asset management fees and/or performance fees.

Go-to-market motion1 record

Distribution channels2 records

Soleus Capital product offering

Product offering

Core offering

Soleus Capital is a healthcare-focused investment firm that manages a multi-fund platform spanning the entire healthcare lifecycle, from developmental-stage through commercial-stage companies. It invests across biotech, medtech, diagnostics, and genomics via private equity funds, a public fund, a credit opportunities fund, and special purpose vehicles, executing strategies such as PIPEs, private placements, public-equity long/short positions, and structured royalty financings.

Product overview

Soleus Capital is a healthcare investment firm that operates a multi-fund platform spanning the healthcare lifecycle, from development-stage companies through commercial companies. Its offering is organized as a platform-plus-modules architecture comprising two investor-portal-hosted suites: a Matrix-hosted suite covering the Public Funds, Private Equity Fund III, and Credit Opportunities Fund I, and an Altar Return-hosted suite covering Private Equity Fund I, Private Equity Fund II, and SPV vehicles. The firm invests across biotech, medtech, diagnostics, and genomics.

Differentiator

Problem solved

Functional benefit

Products and services

  • Public Funds

Quantifiable outcome

  • Led an oversubscribed $30 million private placement for Aprea Therapeutics (May 2026)
  • +6 more outcomes

Companies that use Soleus Capital

Customer profile

Segments2 records

Ideal customer profiles2 records

Soleus Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Soleus Capital partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Soleus Capital competitors and assessment

Company assessment

Direct peers

  • RA Capital Management: Healthcare-dedicated crossover fund investing across public and private biotech via PIPEs, private placements, and follow-ons. Co-invested with Soleus in Parabilis ($305M Series F), Prelude ($90M offering), and Adlai Nortye, making it a directly comparable sponsor in the same niche.
  • Perceptive Advisors: Healthcare-focused investment manager running life-sciences hedge and private credit strategies with biotech PIPE and private placement activity. Co-invested with Soleus in Adlai Nortye's $150M placement and reported alongside Soleus in monthly biopharma hedge fund performance rankings.
  • Cormorant Asset Management: Healthcare-dedicated long/short and private equity manager investing across biotech and medtech stages. Co-invested with Soleus in the Parabilis Series F and Adlai Nortye placement, operating with a similarly lean team and crossover structure.
  • RTW Investments: Healthcare/biotech-focused investment firm running public and private strategies, including PIPEs and venture-style investments in clinical-stage companies. Reported alongside Soleus in monthly biopharma hedge fund performance rankings, making it a direct peer in mandate and structure.
  • Frazier Life Sciences: Healthcare-dedicated venture and public equity manager focused on biopharma across development stages. Co-invested with Soleus in Parabilis' $305M Series F and operates with a comparable pure-play life sciences thesis.
  • venBio Partners: Biotech-focused venture and crossover investor participating in private placements and PIPEs across clinical-stage therapeutics. Co-invested with Soleus in Parabilis' Series F, sharing the dedicated healthcare/life sciences mandate.
  • AIGH Capital Management: Healthcare-focused investment manager actively participating in biotech PIPE and private placement financings. Co-invested with Soleus in Quoin Pharmaceuticals' $104.5M placement, operating with a similar crossover mandate.

Broad incumbents

  • OrbiMed Advisors: One of the largest dedicated healthcare investment firms globally, operating venture, growth, credit, and public equity strategies across biotech, medtech, and diagnostics. Broad incumbent that shares Soleus's vertical focus but operates at significantly larger AUM scale and broader strategy mix.
  • Baker Bros. Advisors: Healthcare-focused long/short equity and venture manager with deep biotech specialization and large AUM. A broad incumbent peer that competes for the same PIPE and private placement opportunities as Soleus but at substantially larger scale.
  • ARCH Venture Partners: Pioneering healthcare/tech venture firm co-leading large crossover rounds including Parabilis' $305M Series F alongside Soleus. A broad incumbent that competes for similar early- and growth-stage life sciences opportunities but with a venture-primary rather than crossover/PIPE model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Soleus Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Soleus Capital leadership team

Management profile

Number of profiles

Profiles1 record

Soleus Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Soleus Capital M&A and investment

M&A and investment

M&A

Investments95 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Soleus Capital

What does Soleus Capital do?

Soleus Capital is a healthcare-focused investment firm that manages a multi-fund platform spanning the entire healthcare lifecycle, from developmental-stage through commercial-stage companies. It invests across biotech, medtech, diagnostics, and genomics via private equity funds, a public fund, a credit opportunities fund, and special purpose vehicles, executing strategies such as PIPEs, private placements, public-equity long/short positions, and structured royalty financings.

Is Soleus Capital a public or private company?

Soleus Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Soleus Capital founded?

Soleus Capital was founded in 2018. It employs 11 to 50 people.

Where is Soleus Capital based?

Soleus Capital is headquartered in Greenwich, United States, in the North America region.

How does Soleus Capital make money?

Three revenue lines are on record. Investment returns / hedge fund performance is the primary driver. The others are royalty financing income and fund management fees.

Who are Soleus Capital's main competitors?

Direct peers on record are RA Capital Management, Perceptive Advisors, Cormorant Asset Management, RTW Investments, Frazier Life Sciences, venBio Partners and AIGH Capital Management. Broad incumbents are OrbiMed Advisors, Baker Bros. Advisors and ARCH Venture Partners.

Does Soleus Capital have an API?

No public API is recorded for Soleus Capital.

What industry is Soleus Capital in?

Soleus Capital's product category is Healthcare Private Equity / Life Sciences Investment Management. Its primary akta.pro industry code is FSAKAGAB, SME Term Loans & Growth Capital. Its NAICS code is 525 and its SIC code is 6159.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireBioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus CapitalBioLineRx sold its 14.4% royalty interest in APHEXDA to Soleus Capital for $5.6 million, excluding the original licensor's 3.6% share. Proceeds will fund GLIX1's Phase 1/2a trial and working capital, with the deal expected to close on November 30, 2026.BioSpaceAethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic DermatitisAethlon Medical and North Immunology announced a merger to advance NOR-101, a bispecific antibody for atopic dermatitis. The deal includes an oversubscribed $180 million private placement and is expected to close in Q1 2027. Phase 1a of NOR-101 is planned for Q1 2027, with topline data expected in 2028.PR NewswireAethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic DermatitisAethlon Medical and North Immunology announced a merger to advance NOR-101, a bispecific antibody for atopic dermatitis. The deal includes an oversubscribed $180 million private placement and is expected to close in Q1 2027. Phase 1a trials are planned for Q1 2027, with topline data expected in 2028.citybizBridge to Life Closes on $110M to Advance Liver TransplantationBridge to Life has closed an $110 million Series C and debt financing round led by Soleus Capital and Lauxera Capital Partners to advance its VitaSmart liver preservation device. The funding supports rapid adoption of the FDA-cleared HOPE system, expansion into other solid organ transplants, and the development of a proprietary viability assessment tool. Proceeds will also be used to refinance existing credit facilities and scale global operations.InvestorsinhealthcareUS: Bridge to Life completes US$110m Series C and debt financing to fuel the company’s VitaSmart launchBridge to Life, a US-based organ preservation and perfusion technology company, completed a US$110m Series C and debt financing. The equity financing was led by new investor Soleus Capital, with participation from Paris- and US-based investors. The funds will fuel the company's VitaSmart launch.Pulse 2.0Bridge To Life Raises $110 Million Series C And Debt Financing Led By Soleus CapitalBridge to Life raised $110 million in Series C equity and debt financing led by Soleus Capital to accelerate the commercialization of its VitaSmart Hypothermic Oxygenated Perfusion System. The company reported that adoption of the FDA-cleared liver transplantation device has exceeded expectations, with rapid uptake among academic transplant centers. Proceeds will fund field expansion, working capital for U.S. deployment, and the development of a proprietary organ viability assessment technology.FinSMEsBridge to Life Raises $110M in Series C FundingBridge to Life raised $110M in Series C and debt financing led by Soleus Capital. The company will use the funds to launch its VitaSmart system, expand its field team, and advance its product pipeline.MorningstarBridge to Life Raises $110 Million to Make Hypothermic Oxygenated Perfusion the Standard of Care in Liver Transplantation and BeyondBridge to Life completed a $110 million Series C and debt financing led by Soleus Capital. Proceeds will fund the VitaSmart hypothermic oxygenated perfusion system's rollout to U.S. transplant centers and advance a viability assessment tool. The company plans to expand its organ preservation portfolio beyond liver transplantation.PR NewswireBridge to Life Raises $110 Million to Make Hypothermic Oxygenated Perfusion the Standard of Care in Liver Transplantation and BeyondBridge to Life completed a $110 million Series C and debt financing led by Soleus Capital. Proceeds will fund the VitaSmart hypothermic oxygenated perfusion system's U.S. rollout and advance a viability assessment tool. The company plans to expand its organ preservation portfolio beyond liver transplantation.GoogleBridge to Life Raises $110 Million to Make Hypothermic Oxygenated Perfusion the Standard of Care in Liver Transplantation and BeyondBridge to Life completed a $110 million Series C and debt financing led by Soleus Capital. Proceeds will scale the VitaSmart hypothermic oxygenated perfusion system to U.S. transplant centers and fund a viability assessment tool and broader organ preservation pipeline.